93272-49-2

Basic information

• Product Name: 2-[3-(oxiran-2-yl)propyl]-1H-isoindole-1,3(2H)-dione
• CAS NO: 93272-49-2
• Molecular Formula: C₁₃H₁₃NO₃
• Molecular Weight: 231.2472
• Mol File: 93272-49-2.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 370.8°C at 760 mmHg
• Flash Point: 178.1°C
• Density: 1.306g/cm³
• Vapor Pressure: 1.08E-05mmHg at 25°C
• Refractive Index: 1.598
• CAS DataBase Reference: 2-[3-(oxiran-2-yl)propyl]-1H-isoindole-1,3(2H)-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 2-[3-(oxiran-2-yl)propyl]-1H-isoindole-1,3(2H)-dione(93272-49-2)
• EPA Substance Registry System: 2-[3-(oxiran-2-yl)propyl]-1H-isoindole-1,3(2H)-dione(93272-49-2)

Safety Data

• Hazardous Substances Data: 93272-49-2(Hazardous Substances Data)

Usage

General Description

2-[3-(oxiran-2-yl)propyl]-1H-isoindole-1,3(2H)-dione is a chemical compound with the molecular formula C13H13NO3. It is a derivative of isoindole and contains a propyl group with an oxiran-2-yl substituent. 2-[3-(oxiran-2-yl)propyl]-1H-isoindole-1,3(2H)-dione is used in organic synthesis and pharmaceutical research, where its unique structure may be utilized for specific biological or chemical interactions. The oxiran-2-yl group, also known as an epoxy group, is a three-membered cyclic ether that can undergo various reactions, making this compound potentially useful in a wide range of applications. Its isoindole-1,3(2H)-dione core structure also offers versatility for modification and functionalization, making it a valuable building block in the synthesis of complex organic molecules.

Upstream product

• 7736-25-6 2-(pent-4-enyl)-isoindoline-1,3-dione 
• 821-09-0 n-Pent-4-enyl alcohol 
• 19300-54-0 toluene-4-sulfonic acid pent-4-enyl ester 
• 1074-82-4 potassium phtalimide 
• 1119-51-3 bromopentene 

Downstream Products

• 93272-50-5 2-[4-Hydroxy-5-(2-nitro-imidazol-1-yl)-pentyl]-isoindole-1,3-dione 

Relevant articles and documents

Design, synthesis, and biological evaluation of 2-(benzylamino-2-hydroxyalkyl)isoindoline-1,3-diones derivatives as potential disease-modifying multifunctional anti-Alzheimer agents

The complex nature of Alzheimer's disease calls for multidirectional treatment. Consequently, the search for multi-target-directed ligands may lead to potential drug candidates. The aim of the present study is to seek multifunctional compounds with expected activity against disease-modifying and symptomatic targets. A series of 15 drug-like various substituted derivatives of 2-(benzylamino-2-hydroxyalkyl)isoindoline-1,3-diones was designed by modification of cholinesterase inhibitors toward β-secretase inhibition. All target compounds have been synthesized and tested against eel acetylcholinesterase (eeAChE), equine serum butyrylcholinesterase (eqBuChE), human β-secretase (hBACE-1), and β-amyloid (Aβ-aggregation). The most promising compound, 12 (2-(5-(benzylamino)-4-hydroxypentyl)isoindoline-1,3-dione), displayed inhibitory potency against eeAChE (IC50 = 3.33 μM), hBACE-1 (43.7% at 50 μM), and Aβ-aggregation (24.9% at 10 μM). Molecular modeling studies have revealed possible interaction of compound 12 with the active sites of both enzymes-acetylcholinesterase and β-secretase. In conclusion: modifications of acetylcholinesterase inhibitors led to the discovery of a multipotent anti-Alzheimer's agent, with moderate and balanced potency, capable of inhibiting acetylcholinesterase, a symptomatic target, and disease-modifying targets: β-secretase and Aβ-aggregation.

ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS

Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): (Formula (I)), including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, R1, R2, R3, Z1 and Z2 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS

Compounds having antibacterial activity are disclosed. The compounds have one of the following structures (I) or (II): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, R1, R2, R3 and Z1 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.